Why the study?
How do various pharmacological agents cause acquired Long QT syndrome and what is the underlying cellular mechanism?
Population
Individuals with or at risk for congenital or acquired Long QT syndrome (LQTS)
Design
Review
Authors
Loading...
Clinicians should screen for IKr/HERG blockers to mitigate acquired LQTS risk; leaves open optimization of preclinical safety assays.
How do various pharmacological agents cause acquired Long QT syndrome and what is the underlying cellular mechanism?
Understanding that acquired LQTS is primarily driven by IKr/HERG channel blockade highlights the need for clinicians to be aware of QT-prolonging drugs and for developers to design safer compounds.
Witchel et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: